DAFTAR PUSTAKA

1. Sung H, Ferlay J, Siegel RL, *et al*. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209-249.

2. Patey D. *Thoracic Tumours, WHO Classification of Tumours*. Vol 1. 5th ed.; 2021.

3. Knight SB, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. *Open Biol*. 2017;7(9).

4. Robot RY, Durry MF, Kairupan CF. Morfologi, Patogenesis, dan Imunoterapi Kanker Paru Tipe Adenokarsinoma. *Med Scope J*. 2021;3(1):74.

5. Balitbangkes RI. Laporan Riskesdas 2018 Nasional.pdf. *Lemb Penerbit Balitbangkes*. 2018.

6. Kementrian Kesehatan. Pusat Data dan Informasi Kementrian Kesehatan RI. Stop Kanker. 2015.

7. Dewi A, Thabrany H, Satrya A, Gemala Chairunnisa Puteri, Fattah RA, Novitasari D. Pusat Kajian Jaminan Sosial Universitas Indonesia (PKJS-UI). *Pkjs-Ui*. 2021:1-29.

8. Ananda RR, Ermayanti S. Artikel Penelitian Hubungan Staging Kanker Paru dengan Skala Nyeri pada Pasien Kanker Paru yang Dirawat di Bagian Paru RSUP DR M Djamil Padang. 2018;7(3):430-435.

9. Chen Z, Zhao N, Wang Q, *et al*. Pd-l1 protein expression and gene amplification correlate with the clinicopathological characteristics and prognosis of lung

squamous cell carcinoma. *Cancer Manag Res*. 2021;13:6365-6375.

10. Cai X, Yu H, Cai Y, Zhang B, Zhou Y. New first-line treatment strategies for advanced lung squamous cell carcinoma. *Transl Lung Cancer Res*. 2020;9(2):414-417.

11. Fernández-Trujillo L, Garcia-Robledo JE, Zúñiga-Restrepo V, Sua LF. Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series. *Respir Med Case Reports*. 2020;30.

12. Vinay, Kumar, Abbas Abul AJ. Robbins and Cotran Pathologic Basic of Disease. In: ninth. Canada: Elsevier; :754-758.

13. Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. *J Hematol Oncol*. 2019;12(1):1-13. doi:10.1186/s13045-019-0779-5

14. Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. *Mol Cancer*. 2019;18(1):1-17.

15. Heymann JJ, Bulman WA, Swinarski D, *et al*. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. *Cancer Cytopathol*. 2017;125(12):896-907.

16. Alexander M, Kim SY, Cheng H. Update 2020: Management of Non-Small Cell Lung Cancer. *Lung*. 2020;198(6):897-907.

17. Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. *J Biomed Sci*. 2017:1-11.

18. Takada K, Okamoto T, Toyokawa G, et al. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. *Lung Cancer*. 2017;104:7-

15.

19. Zhou C, Tang J, Sun H, *et al*. PD-L1 expression as poor prognostic factor in patients with nonsquamous non-small cell lung cancer. *Oncotarget*. 2017;8(35):58457-58468.

20. Ameratunga M, Asadi K, Lin X, *et al*. PD-L1 and Tumor infiltrating lymphocytes as prognostic markers in resected NSCLC. *PLoS One*. 2016;11(4):1-13.

21. Boloker G, Wang C, Zhang J. Updated statistics of lung and bronchus cancer in United States (2018). *J Thorac Dis*. 2018;10(3):1158-1161.

22. Corrin B. *Practical Pulmonary Pathology*. Vol 58. Elsevier; 2008.

23. Tsai JC, Saad OA, Magesh S, *et al*. Tobacco smoke and electronic cigarette vapor alter enhancer rna expression that can regulate the pathogenesis of lung squamous cell carcinoma. *Cancers (Basel)*. 2021;13(16).

24. Samulin Erdem J, Skaug V, Bakke P, Gulsvik A, Haugen A, Zienolddiny S. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer. *BMC Cancer*. 2016;16(1):1-9.

25. Zhang XC, Wang J, Shao GG, *et al*. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. *Nat Commun*. 2019;10(1):1-12.

26. Jusuf A, Wibawanto A, Icksan A, *et al*. Kanker paru : pedoman diagnosis dan penatalaksanaan di Indonesia. 2018:24-30.

27. Kim J, Lee H, Huang BW. Lung Cancer: Diagnosis, Treatment Principles, and

Screening. *Am Fam Physician*. 2022;105(5):487-494.

28. Duma N, Santana-Davila R, Molina JR. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. *Mayo Clin Proc*. 2019;94(8):1623-1640.

29. Suster Saul MCA. *Diagnostic Pathology Thoracic*. second ed. Philadelphia: Elsevier; 2017.

30. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. *Chest*. 2017;151(1):193-203.

31. (IAPI) PDSPI. *Penanganan Spesimen, Diagnosis, Imunohistokimia Dan Patologi Molekuler Pada Karsinoma Paru*. (Lisnawati R, ed.). Jakarta: IAPI; 2019.

32. Andayani N, Julisafrida L. Peranan Immunoterapi Pada Kanker Paru. *J Kedokt Syiah Kuala*. 2020;20(2):70-77.

33. Gong J, Chehrazi-raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy : a comprehensive review of registration trials and future considerations. *J Immunother Cancer*. 2018:1-18.

34. Pan Y, Han H, Labbe KE, Zhang H, Wong KK. Recent advances in preclinical models for lung squamous cell carcinoma. *Oncogene*. 2021;40(16):2817-2829.

35. Gandhi L, Rodriguez D, Gadgeel S E. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer _ NEJM. 2018.

36. Wang A, Wang HY, Liu Y, *et al*. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis. *Eur J Surg Oncol*. 2015;41(4):450-456.

37. Wu T, Dai Y. Tumor microenvironment and therapeutic response. *Cancer Lett*. 2017;387:61-68.

38. Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. *Semin Cancer Biol*. 2012;22(3):234-249.

39. Chew V, Toh HC, Abastado JP. Immune microenvironment in tumor progression: Characteristics and challenges for therapy. *J Oncol*. 2012;2012.

40. Lei X, Lei Y, Li JK, *et al*. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. *Cancer Lett*. 2020;470:126-133.

41. Borros Arneth, Loo CH. Tumor microenvironment. *Mass Transp Nanocarriers*. 2020:185-219.

42. Wahid S, Miskad UA. *Imunologi Lebih Mudah Dipahami*. cetakan ke. (Wijaya A, ed.). Makassar: Brilian Internasional Surabaya; 2016.

43. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. *Curr Opin Immunol*. 2014;27(1):16-25.

44. Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. *Br J Cancer*. 2019;121(1):5-14.

45. Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, Ramakrishna S. Immune system: A double-edged sword in cancer. *Inflamm Res*. 2013;62(9):823-834.

46. Eisel D, Das K, Dickes E, König R, Osen W, Eichmüller SB. Cognate interaction

with CD4+ T cells instructs tumor-associated macrophages to acquire M1-like phenotype. *Front Immunol*. 2019;10(FEB).

47. Fu C, Jiang A. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. *Front Immunol*. 2018;9(December):3059.

48. Maimela NR, Liu S, Zhang Y. Fates of CD8+ T cells in Tumor Microenvironment. *Comput Struct Biotechnol J*. 2019;17:1-13.

49. Abbas Abul, Lichtman Andrew PS. Basic immnology: functions and disorders of the immnune system. In: 6th ed. Elsevier; 2015.

50. Mendelsohn J, Gray JW, Israel MA. *The Molecular Basis of Cancer*.

51. Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. *Curr Opin Immunol*. 2016;39:1-6.

52. Abbas Abul, Lichtman Andrew PS. Cellular and Molecular Immunology. 2018.

53. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. *Am J Clin Oncol Cancer Clin Trials*. 2016;39(1):98-106.

54. Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. Pd-L1. *J Clin Pathol*. 2018;71(3):189-194.

55. Buchbinder EI, Desai N. PD-1PD-L1 immune checkpoint Potential target for cancertherapy.pdf. *Am J Clin Oncol*. 2016;39(1):98-106.

56. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: A novel role of pro-survival signalling in cancer. *Ann Oncol*. 2016;27(3):409-416.

57. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. *Nat Rev Immunol*. 2015;15(8):486-499.

58. Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T. Genetic , transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer : biology and clinical correlations. *Oncogene*. 2018:4639-4661.

59. Alsaab HO, Sau S, Alzhrani R, *et al*. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. *Front Pharmacol*. 2017;8(AUG):1-15.

60. Yu W, Hua Y, Qiu H, *et al*. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. *Cell Death Dis*. 2020;11(7).

61. Teixidó C, Vilariño N, Reyes R, Reguart N. PD-L1 expression testing in non-small cell lung cancer. *Ther Adv Med Oncol*. 2018;10:1-17.

62. Albitar M, Sudarsanam S, Ma W, *et al*. Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer. *Oncotarget*. 2018;9(17):13682-13693.

63. M. C, H. K, J. Z, *et al*. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. *Ann Oncol*. 2017;28(1):83-89.

64. Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. *Onco Targets Ther*. 2016;9:5023-5039.

65. Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. *Oral Oncol*. 2015;51(3):221-228.

66. Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. KRAS-Mutant non-small cell lung cancer: From biology to therapy. *Lung Cancer*. 2018;124(July):53-64.

67. Sastroasmoro I. *Dasar-Dasar Metodologi Penelitian Klinis*. Jakarta: Sagung seto; 2011.

68. Nuryadi, Astuti TD, Utami ES, Budiantara M. *Buku Ajar Dasar-Dasar Statistik Penelitian*.; 2017.

69. Hulma MA, Basyar M, Mulyani H. Hubungan Karakteristik Penderita dengan Gambaran Sitopatologi pada Kasus Karsinoma Paru yang Dirawat di RSUP Dr. M. Djamil Padang. *J Kesehat Andalas*. 2014;3(2):196-201.

70. Yusuf Anwar ES. Dasar-dasar Diagnosis Kanker Paru.pdf. In: *Seri Buku Ajar Onkologi Thoraks*. Jakarta; 2017:9-20.

71. Agilent. PD-L1 IHC 22C3 pharmDx Interpretation Manual – Non-small Cell Lung Cancer (NSCLC). *Agil Techologies*. 2019:6,22,23,24.

72. Janzic U, Kern I, Janzic A, Cavka L, Cufer T. PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung. *Radiol Oncol*. 2017;51(3):357-362.

73. Kirmani N, Jamil K, Naidu MUR. Occupational and environmental carcinogens in epidemiology of lung cancer in South Indian population. *Biol Med*. 2010;2(4):1-11.

74. Dubey NK, Kumar S. Indian Journal of Agriculture ENVIRONMENTAL RISK FACTOR LINKED TO THE GENESIS OF. 2019;(November).

75. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. *Am J*

Cancer Res. 2020;10(3):727-742.

76. Munari E, Zamboni G, Marconi M, et al. PD-L1 expression heterogeneity in non-small cell lung cancer: Evaluation of small biopsies reliability. *Oncotarget*. 2017;8(52):90123-90131.

77. Jöhrens K, Rüschoff J. The challenge to the pathologist of PD-L1 expression in tumor cells of non-small-cell lung cancer—An overview. *Curr Oncol*. 2021;28(6):5227-5239.